Skip to main content

Table 2 Multivariable adjusted least square (LS) means and 95% confidence interval (CI)s of BMI (kg/m2) according to the distribution of lipid profiles among all breast cancer survivors

From: Association of lipid profile with obesity among breast cancer survivors: a cross-sectional study

  LS meansa and 95% CIs of BMI (kg/m2) by plasma lipid markers
Lipid Profile Tertile 1 Tertile 2 Tertile 3 P-trend
Cholesterol (mmol/L)
 Total-C 23.7 (23.1, 24.3) 23.2 (22.6, 23.8) 22.9 (22.4, 23.6) 0.05
 non-HDL-C 23.4 (22.9, 24.0) 23.3 (22.8, 23.9) 23.1 (22.5, 23.8) 0.56
 Remnant-C 23.3 (22.7, 23.9) 23.3 (22.7, 23.8) 23.4 (22.8, 23.9) 0.79
 VLDL-C 22.8 (22.3, 23.4) 23.6 (22.9, 24.1) 23.5 (22.9, 24.1) 0.17
 Clinical LDL-C 23.7 (23.1, 24.3) 23.3 (22.8, 23.9) 22.8 (22.3, 23.4) 0.05
 LDL-Cb 23.7 (23.1, 24.2) 23.2 (22.6, 23.8) 23.0 (22.4, 23.6) 0.19
 HDL-C 23.5 (22.9, 24.1) 23.7 (23.1, 24.2) 22.7 (22.1, 23.3) 0.03
Triglycerides (mmol/L)
 Total-TG 22.8 (22.2, 23.3) 22.9 (22.4, 23.5) 24.2 (23.6, 24.8)  < 0.001§
 VLDL-TG 22.6 (22.1, 23.2) 23.1 (22.5, 23.7) 24.2 (23.6, 24.7)  < 0.001§
 LDL-TG 22.9 (22.3, 23.5) 23.1 (22.5, 23.7) 23.9 (23.3, 24.4) 0.009
 HDL-TG 22.9 (22.4, 23.6) 23.2 (22.7, 23.8) 23.7 (23.1,24.3) 0.008
Phospholipids (mmol/L)
 Total-PL 23.5 (22.9, 24.0) 23.2 (22.6, 23.7) 23.3 (22.7, 23.9) 0.45
 VLDL-PL 22.8 (22.2, 23.3) 23.3 (22.7, 23.9) 23.8 (23.2, 24.4) 0.009
 LDL-PL 23.7 (23.1, 24.2) 23.2 (22.6, 23.7) 23.1 (22.5, 23.6) 0.17
 HDL-PL 23.4 (22.9, 24.0) 23.5 (22.9, 24.0) 22.9 (22.3, 23.5) 0.62
Cholesteryl esters (mmol/L)
 Total-CE 23.7 (23.1, 24.2) 23.4 (22.8, 23.9) 22.9 (22.3, 23.5) 0.07
 VLDL-CE 22.9 (22.4, 23.5) 23.5 (22.9, 24.1) 23.4 (22.8, 23.9) 0.34
 LDL-CE 23.5 (22.9, 24.1) 23.5 (22.9, 24.1) 22.9 (22.3, 23.5) 0.35
 HDL-CE 23.7 (23.1, 24.2) 23.6 (23.0, 24.2) 22.7 (22.1, 23.2) 0.01
Free Cholesterol (mmol/L)
 Total-FC 23.2 (22.6, 23.8) 23.7 (23.1, 24.2) 22.9 (22.4, 23.6) 0.74
 VLDL-FC 22.8 (22.3, 23.4) 23.3 (23.1, 24.3) 23.7 (23.1, 24.3) 0.04
 LDL-FC 23.9 (23.3, 24.5) 23.2 (22.7, 23.8) 22.8 (22.2, 23.3) 0.005
 HDL-FC 23.5 (22.9, 24.1) 23.3 (22.7, 23.9) 23.0 (22.5, 23.6) 0.13
Total Lipids (mmol/L)
 Total-L 23.4 (22.9, 24.1) 22.9 (22.4, 23.5) 23.5 (22.9, 24.0) 0.83
 VLDL-L 22.9 (22.3, 23.4) 23.0 (22.5, 23.6) 24.0 (23.4, 24.6) 0.002
 LDL-L 23.5 (22.9, 24.1) 23.4 (22.8, 23.9) 23.0 (22.5, 23.6) 0.34
 HDL-L 23.4 (22.8, 24.0) 23.6 (23.0, 24.2) 22.9 (22.4, 23.5) 0.19
Lipoprotein particle (mmol/L)
 Total-LP 23.2 (22.7, 23.8) 23.7 (23.2, 24.3) 22.9 (22.3, 23.5) 0.39
 VLDL-LP 22.9 (22.4, 23.6) 23.1 (22.5, 23.6) 23.9 (23.3, 24.4) 0.01
 LDL-LP 23.3 (22.7, 23.9) 23.2 (22.7, 23.80 23.4 (22.8, 23.9) 0.89
 HDL-LP 23.3 (22.7, 23.8) 23.6 (23.1, 24.2) 22.9 (22.4, 23.6) 0.27
Lipoprotein particle sizes (nm)
 VLDL-p 22.7 (22.2, 23.3) 23.3 (22.7, 23.8) 23.9 (23.3, 24.4) 0.009
 LDL-p 23.7 (23.2, 24.3) 23.3 (22.7, 23.8) 22.9 (22.3, 23.5) 0.09
 HDL-p 23.9 (23.4, 24.5) 23.5 (22.9, 24.0) 22.5 (21.9, 23.1)  < 0.001§
  1. aModels were adjusted for age (years, continuous), menopausal status at BC diagnosis (pre-menopause, post-menopause), highest education completed (middle school, high school, college education and above), ever smoked (no, yes), current alcohol use (no, yes), family history of breast cancer (no, yes), history of chronic disease (no, yes) and physical activity (MET-hours/week, continuous)
  2. bLDL-C was estimated from Friedewald’s equation. Clinical LDL-C and LDL-C are the same biomarker but refer to different definition methods [30]
  3. §P-trend was signifincant at Bonferroni corrected P-value = 0.00147